Key Points
- Director sale: Kristina Leslie sold 2,187 HNGE shares at an average $40.46 for $88,486.02, cutting her stake by 6.25% to 32,813 shares (valued at about $1.33M).
- Quarterly beat and growth: Hinge Health reported EPS of ($0.02) vs. consensus ($0.20) and revenue of $154.21M (up 53.3% YoY), both ahead of analyst expectations.
- Buyback and analyst sentiment: The board authorized a $250M repurchase program (up to 7.2% of shares) while analysts have raised targets, leaving a consensus rating of "Moderate Buy" with a $59.93 target.
Hinge Health Inc. (NYSE:HNGE - Get Free Report) Director Kristina Leslie sold 2,187 shares of the firm's stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $40.46, for a total value of $88,486.02. Following the sale, the director owned 32,813 shares in the company, valued at $1,327,613.98. This trade represents a 6.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Hinge Health Trading Up 6.3%
HNGE stock traded up $2.79 during mid-day trading on Thursday, reaching $46.89. 388,988 shares of the company's stock were exchanged, compared to its average volume of 1,154,060. Hinge Health Inc. has a 12-month low of $33.42 and a 12-month high of $62.18. The firm has a 50 day moving average of $50.21.
Hinge Health (NYSE:HNGE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.18. The company had revenue of $154.21 million for the quarter, compared to analysts' expectations of $142.44 million. The company's revenue for the quarter was up 53.3% compared to the same quarter last year. Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.
Hinge Health declared that its board has approved a stock repurchase program on Wednesday, November 12th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 7.2% of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its shares are undervalued.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the stock. Barclays upped their price objective on shares of Hinge Health from $62.00 to $65.00 and gave the company an "overweight" rating in a report on Wednesday, November 5th. Piper Sandler reissued an "overweight" rating and set a $71.00 target price (up previously from $70.00) on shares of Hinge Health in a research note on Wednesday, November 5th. Canaccord Genuity Group lifted their target price on Hinge Health from $61.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, November 5th. Bank of America raised their price objective on shares of Hinge Health from $42.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Finally, Robert W. Baird assumed coverage on shares of Hinge Health in a research note on Friday, September 5th. They set a "neutral" rating and a $56.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Hinge Health currently has an average rating of "Moderate Buy" and a consensus target price of $59.93.
Get Our Latest Stock Report on Hinge Health
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in HNGE. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Hinge Health in the 2nd quarter valued at approximately $828,000. FNY Investment Advisers LLC purchased a new stake in Hinge Health during the 2nd quarter worth about $310,000. Strategic Blueprint LLC acquired a new position in shares of Hinge Health during the 2nd quarter worth about $346,000. Emerald Advisers LLC acquired a new stake in shares of Hinge Health during the 2nd quarter worth about $108,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in Hinge Health during the second quarter worth approximately $114,000.
About Hinge Health
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
